Bristol-Myers Squibb Company (BMY)

pos +0.00
Today's Range: 49.88 - 50.45 | BMY Avg Daily Volume: 14,328,500
Last Update: 10/21/16 - 4:01 PM EDT
Volume: 0
YTD Performance: -27.29%
Open: $0.00
Previous Close: $50.36
52 Week Range: $49.10 - $77.12
Oustanding Shares: 1,670,858,535
Market Cap: 84,144,435,823
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 7
Moderate Buy 0 0 0 1
Hold 10 10 10 7
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.56 2.65 2.65 2.32
Latest Dividend: 0.38
Latest Dividend Yield: 3.02%
Dividend Ex-Date: 10/05/16
Price Earnings Ratio: 18.05
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
18.05 29.60 29.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-33.75% -19.98% 1.52%
Revenue 4.30 -0.10 -0.02
Net Income -19.60 -0.30 -0.13
EPS -22.50 -0.20 -0.07
Earnings for BMY:
Revenue 16.56B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.65 $0.56 $2.63 $2.90
Number of Analysts 11 7 13 13
High Estimate $0.71 $0.61 $2.70 $3.04
Low Estimate $0.53 $0.51 $2.49 $2.68
Prior Year $0.39 $0.38 $2.01 $2.63
Growth Rate (Year over Year) 65.73% 46.62% 30.85% 10.32%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Vale may be worth following again. Bristol-Myers? Not so much.
Oct 13, 2016 | 7:27 AM EDT
BMY was cut from the Conviction Buy list, Goldman Sachs said. $67 price target. Trial setback adds risk to the Opdivo model.
If nothing else, the beginning of earnings season should provide a bit more consistent price action.
Back from my meetings to find the S&P 500 Index basically traded in a 2-3 point range over the last four hours, which is a statisti…
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
Those who thought we were ready to break down look foolish again.
We tend to attach a stigma to losing trades.
The drug maker long has been a growth stock, but a big drop in market cap has brought it down to a reasonable price with a decent dividend to boot.
A quick-turning reversal pattern is all that is needed to set things in motion.
Sep 12, 2016 | 8:54 AM EDT
Shares of BMY now seen reaching $57, according to Jefferies. Estimates also cut, as the company is facing increased competition. Hold r...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.